How is the evolving understanding of lipoprotein A reshaping our approach to prevention of heart disease?

Our host, Dr. Michael Levi, takes a deep dive into this topic with Dr. Lior Bibas, a cardiologist and critical care physician at Pierre Boucher Hospital and the Montreal Heart Institute.

In this episode, our experts explain why lipoprotein A is gaining prominence as a key risk factor for cardiovascular disease, discussing its unique properties and clinical implications. They share insights from their clinical practices, revealing how a deeper understanding of specific lipid markers is influencing both primary and secondary prevention strategies and aggressive treatment decisions. Tune in for a glimpse into the future of personalized heart care and emerging therapies that could transform treatment.

Don’t miss the conversation!

The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent.

Declaration of conflict of interest:

Dr. Michael Levi:

· None.

Dr. Lior Bibas:

· None.

MAT-CA-2501196 V(1.0) App 09/25

Secondary prevention of atherosclerotic cardiovascular disease (ASCVD) often requires the use of lifelong therapies. How can healthcare providers promote adherence to secondary prevention interventions to help high-risk patients achieve their lipid goals?

Our host, Dr. Liam Brunham, takes a deeper look into this topic with Dr. Tara Sedlak, a cardiologist at Vancouver General Hospital and BC Women's Hospital, and Director of the Leslie Diamond Women's Heart Health Clinic.

Despite the availability of lipid-lowering therapies that reduce the risk of morbidity and mortality, many patients with established ASCVD are not achieving guideline-recommended lipid targets. This episode takes a closer look at some of the factors contributing to this care gap, with a focus on the reasons why patients may be discontinuing their medications. Our experts discuss practical strategies to optimize adherence and secondary prevention for improved outcomes. In addition, they also explore the various ways in which treatments can be personalized to individual patient needs, and how best to support and empower patients in their journey toward optimal lipid management.

Don’t miss the conversation!

The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent.

Declaration of conflict of interest:

Dr. Brunham:

• Direct financial relationship including receipt of honoraria: Sanofi, Amgen, HLS, Pfizer, Ultragenyx, Novartis, Novo Nordisk. Membership on advisory boards or speaker’s bureau: Sanofi, Amgen, HLS, Pfizer, Ultragenyx, Novartis, Novo Nordisk. Funded grants, research, or clinical trials: Amgen, Novartis, Ionis.

Dr. Sedlak:

• Direct financial relationship including receipt of honoraria: Amgen, Novo Nordisk, Sanofi, KYE Pharmaceuticals, Pendopharm, Boehringer Ingelheim, Eli Lilly, Bayer, Novartis, Pfizer. Membership on advisory boards or speaker’s bureau: Amgen, Novo Nordisk, KYE Pharmaceuticals, Boehringer Ingelheim, Lilly.

MAT-CA-2301816 App Dec 2023

Following an acute coronary syndrome like non-ST-elevation myocardial infarction (NSTEMI), primary revascularization approaches are the cornerstone for management. What other immediate secondary prevention strategies can be taken to further reduce the residual risk that remains for these patients?

Our host, Dr. Liam Brunham, takes a deeper look into this topic with Dr. Jean Grégoire, a cardiologist and clinical researcher working in the Interventional Cardiology Service of the Coronary Care Unit at the Montreal Heart Institute, and Associate Clinical Professor at the Université de Montréal’s Faculty of Medicine.

This episode discusses the clinical and anatomical benefits from further intensification of lipid-lowering therapies in high-risk patients, and best practices for management of dyslipidemia post-NSTEMI. Our experts go on to explore some of the clinical evidence supporting earlier use of intensified lipid-lowering therapy in the acute setting—notably, the EPIC-STEMI Study. They also examine how findings from these studies may impact future clinical practice, and how better outcomes may be achieved with more significant reductions in LDL cholesterol.

Don’t miss the conversation!

The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent.

Declaration of conflict of interest:

Dr. Brunham:

• Direct financial relationship including receipt of honoraria: Sanofi, Amgen, HLS, Pfizer, Ultragenyx, Novartis, Novo Nordisk. Membership on advisory boards or speaker’s bureau: Sanofi, Amgen, HLS, Pfizer, Ultragenyx, Novartis, Novo Nordisk. Funded grants, research or clinical trials: Amgen, Novartis, Ionis.

Dr. Grégoire:

• Membership on advisory boards or speaker’s bureau: Amgen, Boehringer Ingelheim, Eli Lilly, HLS, Novartis, Sanofi, Servier.

MAT-CA-2301813 App Dec 2023